| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥8393.4B | ¥8015.2B | +4.7% |
| Operating Income | ¥642.5B | ¥616.5B | +4.2% |
| Ordinary Income | ¥678.1B | ¥649.2B | +4.5% |
| Net Income | ¥428.4B | ¥414.7B | +3.3% |
| ROE | 8.1% | 8.0% | - |
FY2025 Q3 cumulative results: Revenue 839.3B yen (YoY +4.7%), Operating Income 64.2B yen (YoY +4.2%), Ordinary Income 67.8B yen (YoY +4.5%), Net Income 42.8B yen (YoY +3.3%). The company maintained revenue growth driven by strong sales at the Matsumoto Kiyoshi Group segment, which contributed 53.4B yen in external sales. Basic EPS increased 6.2% to 106.79 yen, outpacing net income growth due to share count optimization. The gross profit margin of 35.0% remained at high levels, though operating margin of 7.7% remained flat year-over-year. The company demonstrated continued profitability expansion across core retail pharmacy operations, with cash and deposits standing at 99.2B yen supporting financial stability.
Revenue growth of 4.7% to 839.3B yen was primarily driven by the Matsumoto Kiyoshi Group segment, which increased sales by 6.5% to 534.4B yen, while the Cocokara Fine Group segment declined slightly by 0.4% to 295.6B yen. The newly consolidated And Company segment contributed 6.6B yen following the acquisition of Shinseido Pharmacy. Revenue growth was supported by external customer sales expansion, with segment inter-company transactions eliminated at 52.2B yen. Cost of sales increased 4.6% to 545.5B yen, resulting in gross profit of 293.8B yen (gross margin 35.0%, stable YoY). SG&A expenses rose 4.5% to 229.6B yen, with significant components including salaries of 85.4B yen and rent expenses of 59.3B yen, reflecting the fixed-cost structure of store-based operations.
Operating income increased 4.2% to 64.2B yen, with operating margin maintained at 7.7%. The Matsumoto Kiyoshi Group segment generated operating income of 44.7B yen (margin 8.4%), while Cocokara Fine Group produced 17.9B yen (margin 6.1%). The Management Support segment showed operating income decline to 18.2B yen from 20.6B yen prior year, reflecting internal cost allocation adjustments. Ordinary income of 67.8B yen exceeded operating income due to non-operating income of 3.7B yen, including interest income of 0.2B yen and dividend income of 0.4B yen. Financial costs remained minimal at 0.1B yen interest expense.
Net income of 42.8B yen represents a 3.3% increase, with income tax expense of 24.3B yen (effective tax rate 36.2%). Extraordinary losses totaled 0.7B yen, including impairment losses of 0.1B yen on underperforming stores and disaster losses of 0.1B yen, both representing non-recurring factors. The gap between ordinary income (67.8B yen) and net income (42.8B yen) of 25.0B yen is primarily attributable to the tax burden, with no material extraordinary items distorting the earnings quality. This represents a revenue-up/profit-up pattern, with all profit levels advancing in line with sales growth.
The Matsumoto Kiyoshi Group segment is the core business, contributing 63.7% of total revenue at 534.4B yen and generating operating income of 44.7B yen with an operating margin of 8.4%. This segment demonstrated robust growth of 6.5% YoY, with operating income increasing 5.4% from 42.5B yen, reflecting strong operational execution and brand strength. The Cocokara Fine Group segment generated revenue of 295.6B yen (35.2% share) and operating income of 17.9B yen with a margin of 6.1%, slightly below the Matsumoto Kiyoshi margin. This segment experienced a minor revenue decline of 0.4%, with operating income falling 3.5% from 18.6B yen, indicating competitive pressures or operational challenges. The newly added And Company segment contributed 6.6B yen in revenue with operating income of 0.1B yen (margin 2.0%), reflecting the early stage of integration following the Shinseido Pharmacy acquisition. The Management Support segment, representing internal services, recorded revenue of 524.4B yen (largely inter-segment) with operating income of 18.2B yen. Material margin differences exist between segments, with the Matsumoto Kiyoshi Group's 8.4% margin exceeding Cocokara Fine's 6.1% by 2.3 percentage points, suggesting operational efficiency advantages or better market positioning in the former.
[Profitability] Operating margin remained at 7.7%, consistent with the prior year level, while net profit margin stood at 5.1%, indicating stable profitability structure. ROE of 8.1% reflects moderate shareholder return efficiency, with DuPont decomposition showing net profit margin of 5.1%, total asset turnover of 1.140x, and financial leverage of 1.39x. The ROE level remains below the retail industry median, suggesting room for improvement in capital efficiency. Gross margin of 35.0% demonstrates strong pricing power and product mix management in the pharmacy retail sector. [Cash Quality] Cash and deposits totaled 99.2B yen, covering short-term borrowings of 1.5B yen by 65.7x, ensuring robust liquidity. Working capital of 207.2B yen provides comfortable operational buffer. [Investment Efficiency] Total asset turnover of 1.140x indicates effective asset utilization, though inventory turnover of 107 days exceeds the 90-day threshold, warranting monitoring for potential obsolescence risk. Receivables turnover days stood at 33 days and payables turnover at 84 days. [Financial Health] Equity ratio of 72.0% significantly exceeds the retail industry median of 56.8%, reflecting conservative capital structure. Current ratio of 217.8% and quick ratio of 126.5% both indicate strong liquidity positions. Interest-bearing debt remains minimal at 1.5B yen, resulting in an extremely low debt-to-equity ratio and interest coverage exceeding 1,000x, demonstrating minimal financial leverage risk.
Cash and deposits decreased 11.3B yen YoY to 99.2B yen, with operating profit growth contributing to cash accumulation offset by strategic deployment. The balance sheet reveals working capital increased to 207.2B yen, driven by inventory accumulation of 160.6B yen, reflecting either sales expansion preparations or slower turnover. Inventories rose 11.4% to 160.6B yen, extending inventory days to 107 days from prior levels, indicating potential cash conversion cycle elongation. Trade payables increased 3.3% to 126.4B yen, suggesting continued effective supplier credit utilization though at a slower pace than inventory growth. The company maintained strong short-term debt coverage with cash-to-short-term-borrowings ratio of 65.7x. Total assets increased 3.3% to 736.2B yen, with non-current assets rising to 353.0B yen primarily due to goodwill of 100.5B yen and intangible assets of 130.7B yen following the And Company consolidation. Property, plant and equipment stood at 115.5B yen, supporting the store network infrastructure. Retained earnings grew to 361.3B yen, reflecting cumulative profit retention. The increase in inventories relative to sales growth signals potential working capital efficiency deterioration, though robust cash reserves provide cushion for operational flexibility.
Ordinary income of 67.8B yen versus operating income of 64.2B yen shows non-operating net contribution of approximately 3.6B yen, representing a modest 0.4% of revenue. This comprises primarily interest income of 0.2B yen, dividend income of 0.4B yen, and other non-operating income of 0.7B yen, offset by minimal interest expenses of 0.1B yen. The non-operating income composition reflects primarily investment returns and financial income rather than volatile one-time gains, supporting earnings sustainability. Extraordinary losses totaled 0.7B yen, including impairment losses of 0.1B yen on underperforming retail locations and disaster losses of 0.1B yen, both representing non-recurring factors at immaterial levels. The modest gap between operating income and ordinary income indicates core business operations drive profitability without significant dependency on non-operating sources. The effective tax rate of 36.2% on profit before tax of 67.1B yen appears elevated but consistent with standard corporate tax rates. While operating cash flow data is unavailable for quarterly reporting, the stable cash position and minimal debt burden suggest adequate cash generation supports reported earnings. The inventory buildup of 160.6B yen warrants monitoring for potential future write-downs, though no material impairment was recorded in the current period.
Progress rate versus full-year guidance shows Revenue at 76.3% (839.3B yen vs. 1,100.0B yen target), Operating Income at 75.1% (64.2B yen vs. 85.5B yen target), and Ordinary Income at 75.8% (67.8B yen vs. 89.5B yen target) through Q3. Against the standard 75% benchmark for Q3 cumulative, revenue and ordinary income track slightly above target while operating income aligns closely with plan. The company maintained its full-year guidance without revision during Q3, indicating management confidence in achieving FY2025 targets of 1,100.0B yen revenue (+3.6% YoY), 85.5B yen operating income (+4.2% YoY), and 89.5B yen ordinary income (+3.7% YoY). The forecast implies Q4 revenue of 260.7B yen and operating income of 21.3B yen, representing modest sequential acceleration. EPS forecast of 141.67 yen implies full-year net income of 56.5B yen. The consistent progress rates across profit levels and absence of downward revision suggest the company is tracking toward targets, though Q4 execution remains critical to achieve the annual plan.
Annual dividend forecast stands at 24.00 yen per share for FY2025, compared to the prior year dividend. Based on the forecast EPS of 141.67 yen, the payout ratio calculates to 16.9%, reflecting conservative dividend policy with substantial retained earnings for reinvestment. Using the current period net income of 42.8B yen and outstanding shares of 410.3 million (excluding treasury shares of 12.3 million), the interim and year-end dividends total approximately 9.6B yen, resulting in a calculated payout ratio of 22.4% based on nine-month earnings. No share buyback program was disclosed in the current reporting period. The total return ratio remains equivalent to the payout ratio in the absence of buybacks. The conservative payout ratio combined with strong cash position of 99.2B yen and minimal debt provides ample capacity for dividend sustainability and potential future increases, while retaining capital for store network expansion and M&A activities such as the recent Shinseido Pharmacy acquisition.
Inventory management risk: Inventory turnover extended to 107 days, exceeding the 90-day alert threshold by 18.9%, with total inventories of 160.6B yen representing elevated obsolescence and markdown exposure. The 11.4% YoY inventory growth outpacing the 4.7% revenue growth signals potential demand-supply mismatch or category mix deterioration. Store network operational risk: The store-based business model with rent expenses of 59.3B yen and employee costs of 85.4B yen creates high fixed-cost leverage, exposing profitability to same-store sales fluctuations and competitive dynamics. Impairment losses of 0.1B yen on underperforming locations indicate ongoing portfolio optimization needs. Integration and goodwill risk: The And Company segment consolidation generated provisional goodwill of 5.8B yen (total goodwill 100.5B yen), with final purchase price allocation pending. Integration execution challenges or underperformance could trigger future impairment charges, while the substantial intangible asset base of 130.7B yen requires ongoing monitoring for recoverability.
[Industry Position] (Reference - Proprietary Analysis)
The company demonstrates superior profitability and financial stability relative to retail industry peers, while exhibiting areas warranting operational attention.
Profitability: ROE 8.1% substantially exceeds the retail industry median of 2.9% (2025-Q3, n=16), reflecting above-average shareholder returns despite room for further improvement. Operating Margin 7.7% significantly surpasses the industry median of 3.9% (IQR: 1.2%-8.9%), positioning the company in the upper quartile of retail profitability. Net Profit Margin 5.1% exceeds the industry median of 2.2% (IQR: 0.2%-5.7%) by 2.9 percentage points, demonstrating strong bottom-line conversion.
Financial Health: Equity Ratio 72.0% considerably exceeds the industry median of 56.8% (IQR: 39.2%-64.5%), indicating conservative capital structure and financial resilience. Current Ratio 217.8% surpasses the industry median of 1.93x, though presented in different units, reflects robust liquidity management. The minimal debt burden contrasts with industry median Net Debt/EBITDA of -0.41x, positioning the company as essentially debt-free.
Efficiency: Asset Turnover 1.140x exceeds the industry median of 0.95x, indicating effective asset utilization relative to peers. However, Inventory Turnover of 107 days exceeds the industry median of 96 days (IQR: 26-123 days), placing the company near the upper quartile threshold and suggesting inventory management as a relative weakness. Working Capital Turnover of 90 days exceeds the industry median of 32 days significantly, warranting operational focus.
Growth: Revenue Growth of 4.7% exceeds the industry median of 3.0% (IQR: -0.1%-9.2%), positioning the company in the upper half of the growth distribution. EPS Growth of 6.2% substantially exceeds the industry median of -0.29, demonstrating stronger earnings momentum than retail peers.
Overall, the company demonstrates premium profitability margins, conservative financial positioning, and above-median growth, while inventory management efficiency represents the primary area for operational improvement relative to industry benchmarks.
※ Industry: Retail (16 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
Premium profitability with efficiency opportunity: The company maintains operating margin of 7.7% and net margin of 5.1%, both significantly exceeding retail industry medians of 3.9% and 2.2% respectively, demonstrating sustainable competitive advantages in the pharmacy retail segment through strong gross margin of 35.0%. However, inventory days of 107 represent the primary operational challenge, with 11.4% inventory growth outpacing 4.7% revenue growth, creating potential margin pressure from future markdowns or write-downs if not addressed.
Conservative financial structure supporting strategic flexibility: The equity ratio of 72.0% substantially exceeds the industry median of 56.8%, combined with minimal debt of 1.5B yen and cash reserves of 99.2B yen, providing substantial capacity for store network expansion, M&A activity as demonstrated by the Shinseido Pharmacy acquisition, or enhanced shareholder returns. The conservative payout ratio of approximately 17-22% leaves significant room for dividend growth while retaining capital for growth investments.
Segment diversification with integration execution focus: The Matsumoto Kiyoshi Group segment drives profitability with 8.4% operating margin, while the Cocokara Fine segment at 6.1% margin presents opportunity for operational improvement. The newly consolidated And Company segment with provisional goodwill of 5.8B yen requires successful integration execution to realize synergies and avoid future impairment risk, representing both opportunity and execution risk over the medium term.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.